Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
01/14/21 NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
01/06/21 Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
01/06/21 Alkermes Announces Updates to Executive Leadership Team
12/29/20 FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
12/10/20 Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
11/17/20 Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
11/09/20 Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
10/29/20 Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
10/29/20 Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
10/22/20 Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results
10/09/20 FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
10/09/20 Trading in Alkermes Ordinary Shares Halted Today
10/07/20 Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831
09/18/20 Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress
09/14/20 Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience
Displaying 1 - 15 of 795